The variable response to antiseizure medication (ASM) treatment and the numerous drug-
and patient-related factors that must be considered when initiating therapy make drug …

New-onset movement disorders have been frequently reported in association with the use of
antiseizure medications (ASMs). The frequency of specific motor manifestations and the …

Background: Nonadherence to medication is widespread in epilepsy and other chronic
diseases. Studies reporting adherence to antiepileptic medications are very limited in …

Background The new antiseizure medications (ASMs) and non-invasive brain stimulation
(NIBS) are controversial in controlling seizures. So, this network meta-analysis aimed to …

Epilepsy is a neurological disease characterized by excessive and abnormal hyper-
synchrony of electrical discharges of the brain and a predisposition to generate epileptic …

Introduction: Eslicarbazepine acetate (ESL) is a third-generation antiepileptic drug (AED)
approved for adjunctive treatment in adults, children, and adolescents with focal-onset …

Objectives Cenobamate is an antiseizure medication (ASM) approved in Europe as
adjunctive therapy for adults with inadequately controlled focal seizures. This post hoc …

Objectives Eslicarbazepine acetate (ESL) is a once‐daily (QD) oral antiepileptic drug (AED)
for focal‐onset seizures (FOS). Pharmacokinetic (PK) and pharmacodynamic (PD) models …

In this work, we developed and validated the specific, sensitive and simple LC–MS/MS
method for quantification of eslicarbazepine in human plasma. The analyte samples were …

Trials of antiseizure medications involve static group assignments for treatments with pre-
specified durations. We propose a response-adaptive crossover design using basic …